针对成人T细胞白血病/淋巴瘤的新疗法
Zachary D Epstein-Peterson1, Ashwath Gurumurthi2, Steven M Horwitz1
1Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th St., New York, NY 10021, USA; Department of Medicine, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA.
由HTLV-1引起的成人T细胞白血病/淋巴瘤 (ATL) 是罕见的,难以治疗,特别是复发形式. 本综述探讨了复发性/耐药性ATL的新疗法,为更好的结果提供了希望.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 血液学 血液学 血液学
背景情况:
- 成人T细胞白血病/淋巴瘤 (ATL) 是一种成熟的T细胞瘤,与人类T细胞淋巴细胞病毒1型 (HTLV-1) 有关.
- 在特定的全球区域内,ATL是特有的,传播通常通过母乳发生,随后在很小比例的携带者中,在恶性转变之前,有很长的潜伏期.
- 山分类仍然是ATL治疗指南的基石,尽管该疾病的罕见性使大规模临床试验复杂化.
研究的目的:
- 审查当前针对成人T细胞白血病/淋巴瘤 (ATL) 新型治疗剂的现状.
- 专注于复发性和耐火性ATL的治疗策略.
- 检查新兴ATL疗法的作用机制,耐药性模式和临床疗效.
主要方法:
- 对ATL的新型治疗药物的文献综述.
- 对作用和抵抗机制的分析.
- 对复发性和耐火性ATL的临床疗效数据的评估.
主要成果:
- 攻击性ATL亚型的预后不好,中位数存活时间短.
- 异构移植是唯一的治愈选择,但需要深度缓解诱导.
- 复发性ATL的预后很糟糕,原因是化疗阻断性和有限的治疗选择.
结论:
- 新型治疗剂在治疗复发性和耐火性ATL方面表现有前途.
- 了解作用和抗性的机制对于优化治疗至关重要.
- 需要进一步的研究来改善ATL患者的治疗结果,特别是那些耐火性疾病患者.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Tumor Immunotherapy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
